SMA Disease and Treatment Options
SMA (Spinal Muscular Atrophy) is a genetic disease characterized by the degeneration of motor neurons. This disease causes muscle weakness and muscle loss, significantly affecting the daily lives of patients. In recent years, significant developments have been made in the treatment of SMA and new treatment options have emerged.
Available Treatment Options
There are two main treatment options available for SMA disease in Turkey: If you are nusiner ve RisdiplamThese drugs are used to improve the quality of life of patients and slow down the progression of the disease.
- If you are nusiner: It was added to the Foreign Drug List in 2017 and was licensed and included in the reimbursement scope in 2022. This drug offers an effective treatment for SMA disease.
- Risdiplam: This drug, which was added to the list in 2020, is expected to be licensed in 2024. Risdiplam stands out as an important treatment option for SMA disease.
Situation Regarding Zolgensma
Another treatment option for SMA disease Zolgensma However, it was not included in the Foreign Drug List by the SMA Scientific Committee on the grounds that there was no evidence that it was superior to the current treatment. This shows that treatment processes should be supported by scientific data.
The Importance of Scientific Data in Treatment Processes
The SMA Scientific Board closely follows medical developments in the treatment of the disease and bases its decisions on scientific data. Long-term data obtained from international multicenter high-quality clinical studies form the basis of treatment decisions for SMA.
Financial Factors and Treatment Options
The Ministry of Health, while determining the methods to be applied in the treatment of SMA, evaluates the health benefits of the patients and the treatment costs rationally. Turkey, as an important social state in the field of health services, offers its citizens
